COMMUNIQUÉS West-GlobeNewswire

NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
10/01/2025
BOULDER, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, a leader in ultra-sensitive minimal residual disease (MRD) detection technology, today announced the inclusion of circulating tumor DNA (ctDNA) [...]
RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025
10/01/2025
MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced its key [...]
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
10/01/2025
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE [...]
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
10/01/2025
By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare and specialty therapies. With two new members - Innovative Medicines Group and [...]
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
10/01/2025
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending [...]
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
10/01/2025
8th Sachs Annual Neuroscience Innovation Forum 14th Annual LifeSci Advisors Corporate Access Event Invest Securities BioMed Forum 2025 MidCap Events Frankfurt 2025 Bio-Neuroscience 2025 MADRID and CAMBRIDGE, Mass., Jan [...]
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
10/01/2025
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) [...]
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09/01/2025
SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm , a nationally renowned sports [...]
Voting Rights and Shares Capital of the Company
09/01/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Jan. 09, 2025 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
09/01/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 09 janv. 2025 (GLOBE NEWSWIRE) -- Paris, France, le 9 janvier 2025 Place de cotation : [...]
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
09/01/2025
SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, [...]
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
09/01/2025
PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
09/01/2025
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML SAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company [...]
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
09/01/2025
Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary data readouts for [...]
BioV Life Science and Regenerative Medicine International Summit Successfully Concludes, Leading the Future of Regenerative Medicine
09/01/2025
Los Angeles, CA, Jan. 09, 2025 (GLOBE NEWSWIRE) -- On December 22, 2024, the "BioV Life Science and Regenerative Medicine International Summit," a significant event in the life sciences field at the end of 2024, [...]
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
09/01/2025
Priority programs – NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis – set foundation for significant, near-term value creation Phase 3 HAELO study [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2025
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, [...]
Partnering to Save Lives, NMDP and the American Football Coaches Association Promote Student Athlete Philanthropy
09/01/2025
AFCA’s Support of NMDP Get in the Game Invites College Coaches and Student Athletes to Help Give More Patients a Second Chance at Life Through Blood Stem Cell Donations MINNEAPOLIS, Jan. 09, 2025 (GLOBE NEWSWIRE) -- [...]
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs
09/01/2025
– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – [...]

Pages